JP2016053066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016053066A5 JP2016053066A5 JP2015218025A JP2015218025A JP2016053066A5 JP 2016053066 A5 JP2016053066 A5 JP 2016053066A5 JP 2015218025 A JP2015218025 A JP 2015218025A JP 2015218025 A JP2015218025 A JP 2015218025A JP 2016053066 A5 JP2016053066 A5 JP 2016053066A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- halo
- optionally substituted
- alkyl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001475 halogen functional group Chemical group 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 208000002193 Pain Diseases 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 208000011580 syndromic disease Diseases 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 6
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 5
- 208000002780 macular degeneration Diseases 0.000 claims 5
- 230000035939 shock Effects 0.000 claims 5
- 206010020649 Hyperkeratosis Diseases 0.000 claims 4
- 208000019693 Lung disease Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 4
- 230000002685 pulmonary effect Effects 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 3
- 208000001126 Keratosis Diseases 0.000 claims 3
- 208000001294 Nociceptive Pain Diseases 0.000 claims 3
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 239000010425 asbestos Substances 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 230000007812 deficiency Effects 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims 3
- 229910052895 riebeckite Inorganic materials 0.000 claims 3
- 201000004409 schistosomiasis Diseases 0.000 claims 3
- 210000003491 skin Anatomy 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- 108010044267 Abnormal Hemoglobins Proteins 0.000 claims 2
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 2
- 200000000007 Arterial disease Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 2
- 208000012609 Cowden disease Diseases 0.000 claims 2
- 206010048768 Dermatosis Diseases 0.000 claims 2
- 208000037487 Endotoxemia Diseases 0.000 claims 2
- 208000006968 Helminthiasis Diseases 0.000 claims 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 2
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 210000001766 X chromosome Anatomy 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000028831 congenital heart disease Diseases 0.000 claims 2
- 230000000148 hypercalcaemia Effects 0.000 claims 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims 2
- 206010021198 ichthyosis Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims 2
- 201000001245 periodontitis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010063409 Acarodermatitis Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 241000251468 Actinopterygii Species 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000004881 Amebiasis Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 206010001980 Amoebiasis Diseases 0.000 claims 1
- 206010002064 Anaemia macrocytic Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000033116 Asbestos intoxication Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 241000244203 Caenorhabditis elegans Species 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010063094 Cerebral malaria Diseases 0.000 claims 1
- 206010008334 Cervicobrachial syndrome Diseases 0.000 claims 1
- 208000009043 Chemical Burns Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 1
- 206010010099 Combined immunodeficiency Diseases 0.000 claims 1
- 206010010755 Conjunctivitis viral Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 208000008953 Cryptosporidiosis Diseases 0.000 claims 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 claims 1
- 206010061802 Cyclosporidium infection Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 206010063045 Effusion Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000006353 Filariasis Diseases 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 201000007151 Good syndrome Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010021133 Hypoventilation Diseases 0.000 claims 1
- 208000007924 IgA Deficiency Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010023076 Isosporiasis Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010026673 Malignant Pleural Effusion Diseases 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000011682 Mitral valve disease Diseases 0.000 claims 1
- 206010062207 Mycobacterial infection Diseases 0.000 claims 1
- 208000021908 Myocardial disease Diseases 0.000 claims 1
- 241000244206 Nematoda Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000243985 Onchocerca volvulus Species 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 206010033733 Papule Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034487 Pericarditis constrictive Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010035592 Pleural calcification Diseases 0.000 claims 1
- 206010035600 Pleural fibrosis Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010068690 Pulmonary vein occlusion Diseases 0.000 claims 1
- 208000019155 Radiation injury Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 208000009527 Refractory anemia Diseases 0.000 claims 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 241000447727 Scabies Species 0.000 claims 1
- 206010039915 Selective IgA immunodeficiency Diseases 0.000 claims 1
- 206010057863 Selective IgG subclass deficiency Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044269 Toxocariasis Diseases 0.000 claims 1
- 201000005485 Toxoplasmosis Diseases 0.000 claims 1
- 206010044608 Trichiniasis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000005914 Viral Conjunctivitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010002906 aortic stenosis Diseases 0.000 claims 1
- 229910052785 arsenic Inorganic materials 0.000 claims 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims 1
- 206010003441 asbestosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 claims 1
- 201000008680 babesiosis Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000001969 capillary hemangioma Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000000839 constrictive pericarditis Diseases 0.000 claims 1
- 230000009519 contusion Effects 0.000 claims 1
- 201000002641 cyclosporiasis Diseases 0.000 claims 1
- 201000008167 cystoisosporiasis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 201000006592 giardiasis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000000004 hemodynamic effect Effects 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 201000007156 immunoglobulin alpha deficiency Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 201000006437 macrocytic anemia Diseases 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 210000002752 melanocyte Anatomy 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 201000011475 meningoencephalitis Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000008588 molluscum contagiosum Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000002042 onchocerciasis Diseases 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000001185 psoriatic effect Effects 0.000 claims 1
- 210000003492 pulmonary vein Anatomy 0.000 claims 1
- 208000037813 pulmonary venous hypertension Diseases 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000005687 scabies Diseases 0.000 claims 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims 1
- 208000029138 selective IgA deficiency disease Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 208000003982 trichinellosis Diseases 0.000 claims 1
- 201000007588 trichinosis Diseases 0.000 claims 1
- 208000009920 trichuriasis Diseases 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 201000002311 trypanosomiasis Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 230000000304 vasodilatating effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 0 *C(CCC(N1)=O)(C1=O)N(C(*)=Nc1cccc(*)c11)C1=O Chemical compound *C(CCC(N1)=O)(C1=O)N(C(*)=Nc1cccc(*)c11)C1=O 0.000 description 9
- VBLOIBROZDZLFK-UHFFFAOYSA-N CC(C)(C)CC(NCc(cccc1CN=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O Chemical compound CC(C)(C)CC(NCc(cccc1CN=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O VBLOIBROZDZLFK-UHFFFAOYSA-N 0.000 description 1
- URAPUBKKXXHNBT-UHFFFAOYSA-N CC(N(C(CCC(N1)=O)C1=O)C(C12)=O)=NC1C=CC=C2NC(Cc(cc1)ccc1F)=O Chemical compound CC(N(C(CCC(N1)=O)C1=O)C(C12)=O)=NC1C=CC=C2NC(Cc(cc1)ccc1F)=O URAPUBKKXXHNBT-UHFFFAOYSA-N 0.000 description 1
- VRGCBRISRNMEIO-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=NC(C2C=CC=C3NC(COC)=O)C23C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=NC(C2C=CC=C3NC(COC)=O)C23C1=O VRGCBRISRNMEIO-UHFFFAOYSA-N 0.000 description 1
- NGLOKKGTIDTJGG-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=NC(C=CCC2CNC(Cc(cc3)cc(Cl)c3Cl)=O)=C2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=NC(C=CCC2CNC(Cc(cc3)cc(Cl)c3Cl)=O)=C2C1=O NGLOKKGTIDTJGG-UHFFFAOYSA-N 0.000 description 1
- XYBBDBNEKTWZPP-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=NC(C=CCC2CNC(c(cc3)ccc3Cl)=O)=C2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=NC(C=CCC2CNC(c(cc3)ccc3Cl)=O)=C2C1=O XYBBDBNEKTWZPP-UHFFFAOYSA-N 0.000 description 1
- BAEBQMPUNUSFOV-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=NC2C=CC=C(CNC(c3ccc(C(F)(F)F)cc3)=O)C2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=NC2C=CC=C(CNC(c3ccc(C(F)(F)F)cc3)=O)C2C1=O BAEBQMPUNUSFOV-UHFFFAOYSA-N 0.000 description 1
- WDSJIKBKEVHHON-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc(cccc2CNC(Cc3ccccc3)=O)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc(cccc2CNC(Cc3ccccc3)=O)c2C1=O WDSJIKBKEVHHON-UHFFFAOYSA-N 0.000 description 1
- QLCJHKIJKKJYAQ-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc(cccc2NC(COCc3ccccc3)=O)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc(cccc2NC(COCc3ccccc3)=O)c2C1=O QLCJHKIJKKJYAQ-UHFFFAOYSA-N 0.000 description 1
- OVDGQHSOYHQOCH-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(C(F)(F)F)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(C(F)(F)F)c2C1=O OVDGQHSOYHQOCH-UHFFFAOYSA-N 0.000 description 1
- BMHWGXMITMVJBX-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(C3CC3)=O)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(C3CC3)=O)c2C1=O BMHWGXMITMVJBX-UHFFFAOYSA-N 0.000 description 1
- VRLVZWRZNNAQBD-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(CN(C)C)=O)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(CN(C)C)=O)c2C1=O VRLVZWRZNNAQBD-UHFFFAOYSA-N 0.000 description 1
- RLZLEDRWCMJNOJ-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(Cc(cc3)ccc3Cl)=O)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(Cc(cc3)ccc3Cl)=O)c2C1=O RLZLEDRWCMJNOJ-UHFFFAOYSA-N 0.000 description 1
- KJDNVANWIOQHEU-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(Cc3ccc(C(F)(F)F)cc3)=O)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(Cc3ccc(C(F)(F)F)cc3)=O)c2C1=O KJDNVANWIOQHEU-UHFFFAOYSA-N 0.000 description 1
- KAYQARQKPJXWHF-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(c(cc3)cc(Cl)c3Cl)=O)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(c(cc3)cc(Cl)c3Cl)=O)c2C1=O KAYQARQKPJXWHF-UHFFFAOYSA-N 0.000 description 1
- NFJFDBFTXNLNEA-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(c(cc3)ccc3SC(F)(F)F)=O)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(c(cc3)ccc3SC(F)(F)F)=O)c2C1=O NFJFDBFTXNLNEA-UHFFFAOYSA-N 0.000 description 1
- OAOZQNVBMFBYDP-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(c3cccc(C(F)(F)F)c3)=O)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(c3cccc(C(F)(F)F)c3)=O)c2C1=O OAOZQNVBMFBYDP-UHFFFAOYSA-N 0.000 description 1
- NSJDHALUQCPNCG-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(c3cccc(F)c3)=O)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(c3cccc(F)c3)=O)c2C1=O NSJDHALUQCPNCG-UHFFFAOYSA-N 0.000 description 1
- YGZXNOBHFGHBKK-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(c3ccccc3)=O)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(CNC(c3ccccc3)=O)c2C1=O YGZXNOBHFGHBKK-UHFFFAOYSA-N 0.000 description 1
- ZXTQKHPDEFWIIL-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(Cl)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(Cl)c2C1=O ZXTQKHPDEFWIIL-UHFFFAOYSA-N 0.000 description 1
- WPDNSBXGCLUYOK-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(F)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(F)c2C1=O WPDNSBXGCLUYOK-UHFFFAOYSA-N 0.000 description 1
- RSNPAKAFCAAMBH-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(N)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(N)c2C1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 description 1
- WMJCZFOCDPKUSY-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(NC(C3CC3)=O)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(NC(C3CC3)=O)c2C1=O WMJCZFOCDPKUSY-UHFFFAOYSA-N 0.000 description 1
- SOCIFGWTUQIVBJ-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(NC(c3cccc(Cl)c3)=O)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(NC(c3cccc(Cl)c3)=O)c2C1=O SOCIFGWTUQIVBJ-UHFFFAOYSA-N 0.000 description 1
- BUMGMIFCESMJLB-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(OC)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(OC)c2C1=O BUMGMIFCESMJLB-UHFFFAOYSA-N 0.000 description 1
- HEHDONJSLRYCNG-UHFFFAOYSA-N CC(Nc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O Chemical compound CC(Nc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O HEHDONJSLRYCNG-UHFFFAOYSA-N 0.000 description 1
- NYFVOQHYHMLARA-UHFFFAOYSA-N CCC(N1C(CCC(N2)=O)C2=O)=Nc(cccc2C)c2C1=O Chemical compound CCC(N1C(CCC(N2)=O)C2=O)=Nc(cccc2C)c2C1=O NYFVOQHYHMLARA-UHFFFAOYSA-N 0.000 description 1
- LXNJLZACSHYGAT-UHFFFAOYSA-N CCCC(NCc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O Chemical compound CCCC(NCc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O LXNJLZACSHYGAT-UHFFFAOYSA-N 0.000 description 1
- ICQGCVYSAKTZMU-UHFFFAOYSA-N CCCCC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(C)c2C1=O Chemical compound CCCCC(N1C(CCC(N2)=O)C2=O)=Nc2cccc(C)c2C1=O ICQGCVYSAKTZMU-UHFFFAOYSA-N 0.000 description 1
- SZOITVJMMHVYNG-UHFFFAOYSA-N CCCCCCC(NCc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O Chemical compound CCCCCCC(NCc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O SZOITVJMMHVYNG-UHFFFAOYSA-N 0.000 description 1
- IZTDFSVOJYKZNO-UHFFFAOYSA-N CCCCCCC(Nc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O Chemical compound CCCCCCC(Nc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O IZTDFSVOJYKZNO-UHFFFAOYSA-N 0.000 description 1
- PBTABGZAOCPZNU-UHFFFAOYSA-N CCOC(Nc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O Chemical compound CCOC(Nc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O PBTABGZAOCPZNU-UHFFFAOYSA-N 0.000 description 1
- JQUZXXZECCUUIU-UHFFFAOYSA-N CCOCC(Nc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O Chemical compound CCOCC(Nc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O JQUZXXZECCUUIU-UHFFFAOYSA-N 0.000 description 1
- YBEDEOMQBHQZHU-OAHLLOKOSA-N C[C@@](CCC(N1)=O)(C1=O)N(C(C)=Nc1cccc(N)c11)C1=O Chemical compound C[C@@](CCC(N1)=O)(C1=O)N(C(C)=Nc1cccc(N)c11)C1=O YBEDEOMQBHQZHU-OAHLLOKOSA-N 0.000 description 1
- NZEUXMSLYOCMFG-INIZCTEOSA-N C[C@](CCC(N1)=O)(C1=O)N(C(C)=Nc1c2c(C)ccc1)C2=O Chemical compound C[C@](CCC(N1)=O)(C1=O)N(C(C)=Nc1c2c(C)ccc1)C2=O NZEUXMSLYOCMFG-INIZCTEOSA-N 0.000 description 1
- YBEDEOMQBHQZHU-HNNXBMFYSA-N C[C@](CCC(N1)=O)(C1=O)N(C(C)=Nc1cccc(N)c11)C1=O Chemical compound C[C@](CCC(N1)=O)(C1=O)N(C(C)=Nc1cccc(N)c11)C1=O YBEDEOMQBHQZHU-HNNXBMFYSA-N 0.000 description 1
- SXPZYDHEEHEKIK-UHFFFAOYSA-N Cc(cc(cc1)C(NCc(cccc2N=C(C)N3C(CCC(N4)=O)C4=O)c2C3=O)=O)c1Cl Chemical compound Cc(cc(cc1)C(NCc(cccc2N=C(C)N3C(CCC(N4)=O)C4=O)c2C3=O)=O)c1Cl SXPZYDHEEHEKIK-UHFFFAOYSA-N 0.000 description 1
- ASYQIRBAHZVVJJ-UHFFFAOYSA-N Cc(cc1)ccc1C(NCc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O Chemical compound Cc(cc1)ccc1C(NCc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O ASYQIRBAHZVVJJ-UHFFFAOYSA-N 0.000 description 1
- XROMBOPGJOSCPW-UHFFFAOYSA-N Cc(ccc(CC(NCc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O)c1)c1F Chemical compound Cc(ccc(CC(NCc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O)c1)c1F XROMBOPGJOSCPW-UHFFFAOYSA-N 0.000 description 1
- MOTNMBQWUAUDKJ-UHFFFAOYSA-N Cc(ccc(NC(NCc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O)c1)c1Cl Chemical compound Cc(ccc(NC(NCc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O)=O)c1)c1Cl MOTNMBQWUAUDKJ-UHFFFAOYSA-N 0.000 description 1
- ONJPWRCLMUBARN-UHFFFAOYSA-N Cc(cccc1N=C(C(F)(F)F)N2C(CCC(N3)=O)C3=O)c1C2=O Chemical compound Cc(cccc1N=C(C(F)(F)F)N2C(CCC(N3)=O)C3=O)c1C2=O ONJPWRCLMUBARN-UHFFFAOYSA-N 0.000 description 1
- LFQSYKFVAWOSQE-UHFFFAOYSA-N Cc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O Chemical compound Cc(cccc1N=C(C)N2C(CCC(N3)=O)C3=O)c1C2=O LFQSYKFVAWOSQE-UHFFFAOYSA-N 0.000 description 1
- LFQSYKFVAWOSQE-LLVKDONJSA-N Cc(cccc1N=C(C)N2[C@H](CCC(N3)=O)C3=O)c1C2=O Chemical compound Cc(cccc1N=C(C)N2[C@H](CCC(N3)=O)C3=O)c1C2=O LFQSYKFVAWOSQE-LLVKDONJSA-N 0.000 description 1
- DQJASQBQGTWART-UHFFFAOYSA-N Cc(cccc1N=C(c2ccccc2)N2C(CCC(N3)=O)C3=O)c1C2=O Chemical compound Cc(cccc1N=C(c2ccccc2)N2C(CCC(N3)=O)C3=O)c1C2=O DQJASQBQGTWART-UHFFFAOYSA-N 0.000 description 1
- UUWIOBJDQIAPGW-UHFFFAOYSA-N Cc(cccc1N=CN2CC(CCC(N3)=O)C3=O)c1C2=O Chemical compound Cc(cccc1N=CN2CC(CCC(N3)=O)C3=O)c1C2=O UUWIOBJDQIAPGW-UHFFFAOYSA-N 0.000 description 1
- FJTYIZGUVKBWMI-JKSFWZLDSA-N Cc1cccc(C(NCC(C2)=CC=C[C@@]2(C2)N=C(C)N(C(CCC(N3)=O)C3=O)C2=O)=O)c1 Chemical compound Cc1cccc(C(NCC(C2)=CC=C[C@@]2(C2)N=C(C)N(C(CCC(N3)=O)C3=O)C2=O)=O)c1 FJTYIZGUVKBWMI-JKSFWZLDSA-N 0.000 description 1
- IXKSHXGLLNAFSD-UHFFFAOYSA-N Cc1cccc(N=C(N2C(CCC(N3)=O)C3=O)O)c1C2=O Chemical compound Cc1cccc(N=C(N2C(CCC(N3)=O)C3=O)O)c1C2=O IXKSHXGLLNAFSD-UHFFFAOYSA-N 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N NC(c1ccccn1)=O Chemical compound NC(c1ccccn1)=O IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N Nc(cc1)ccc1Cl Chemical compound Nc(cc1)ccc1Cl QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- JOBCWQBLSPZSEQ-UHFFFAOYSA-N O=C(CCC1N(C=Nc2cccc(Cl)c22)C2=O)NC1=O Chemical compound O=C(CCC1N(C=Nc2cccc(Cl)c22)C2=O)NC1=O JOBCWQBLSPZSEQ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84747106P | 2006-09-26 | 2006-09-26 | |
| US60/847,471 | 2006-09-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013210802A Division JP5901599B2 (ja) | 2006-09-26 | 2013-10-08 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017082496A Division JP2017165744A (ja) | 2006-09-26 | 2017-04-19 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016053066A JP2016053066A (ja) | 2016-04-14 |
| JP2016053066A5 true JP2016053066A5 (enExample) | 2016-06-02 |
| JP6133383B2 JP6133383B2 (ja) | 2017-05-24 |
Family
ID=39230813
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530406A Expired - Fee Related JP5388854B2 (ja) | 2006-09-26 | 2007-09-25 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
| JP2013210802A Expired - Fee Related JP5901599B2 (ja) | 2006-09-26 | 2013-10-08 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
| JP2015218025A Expired - Fee Related JP6133383B2 (ja) | 2006-09-26 | 2015-11-06 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
| JP2017082496A Ceased JP2017165744A (ja) | 2006-09-26 | 2017-04-19 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530406A Expired - Fee Related JP5388854B2 (ja) | 2006-09-26 | 2007-09-25 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
| JP2013210802A Expired - Fee Related JP5901599B2 (ja) | 2006-09-26 | 2013-10-08 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017082496A Ceased JP2017165744A (ja) | 2006-09-26 | 2017-04-19 | ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法 |
Country Status (33)
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| MX2009003038A (es) * | 2006-09-26 | 2009-04-15 | Celgene Corp | Derivados de quinazolinona 5-sustituidos como agentes antitumorales. |
| CA2704710C (en) | 2007-09-26 | 2016-02-02 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same |
| US8354417B2 (en) * | 2007-09-26 | 2013-01-15 | Celgene Corporation | Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same |
| US7786171B2 (en) | 2008-04-04 | 2010-08-31 | Abbott Laboratories | Amide derivatives as positive allosteric modulators and methods of use thereof |
| US8835506B2 (en) | 2008-06-05 | 2014-09-16 | Stc.Unm | Methods and related compositions for the treatment of cancer |
| US20100160368A1 (en) | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
| LT2378876T (lt) | 2008-12-19 | 2019-04-25 | Medicis Pharmaceutical Corporation | Mažesnio stiprumo dozės imikvimodo kompozicijos ir trumpi dozavimo režimai, skirti aktininės keratozės gydymui |
| EP2433124B1 (en) * | 2009-05-19 | 2017-03-01 | Vivia Biotech S.L. | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
| JP5645816B2 (ja) | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
| EA025993B1 (ru) | 2009-07-13 | 2017-02-28 | Медисис Фармасьютикал Корпорейшн | Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения остроконечных и перианальных бородавок |
| CN101913846B (zh) * | 2010-08-11 | 2012-05-23 | 昆明理工大学 | 一种用煤泥磷石膏冶金废渣合成陶粒的方法 |
| JP6118273B2 (ja) * | 2011-03-11 | 2017-04-19 | セルジーン コーポレイション | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
| UA113512C2 (xx) * | 2011-03-11 | 2017-02-10 | Тверда форма 3-(5-аміно-2-метил-4-оксо-4h-хіназолін-3-іл)піперидин-2,6-діону і її фармацевтична композиція та застосування | |
| US9090585B2 (en) | 2011-03-28 | 2015-07-28 | Deuterx, Llc | 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds |
| EP2702410A2 (en) | 2011-04-29 | 2014-03-05 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| MX358517B (es) | 2012-06-29 | 2018-08-24 | Celgene Corp | Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon. |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| ES2814952T3 (es) * | 2012-09-04 | 2021-03-29 | Celgene Corp | Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos |
| WO2014039960A1 (en) * | 2012-09-10 | 2014-03-13 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
| CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| AU2014236597A1 (en) | 2013-03-14 | 2015-09-24 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| EP2986322A1 (en) * | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| US9067912B2 (en) | 2013-05-01 | 2015-06-30 | Celgene Corporation | Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,8-dione |
| WO2014179661A1 (en) | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| CN103645259B (zh) * | 2013-12-12 | 2015-03-11 | 深圳海王药业有限公司 | 一种同时测定泊马度胺及其有关物质的方法 |
| US20150196562A1 (en) | 2014-01-15 | 2015-07-16 | Celgene Corporation | Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| JP6615791B2 (ja) | 2014-06-05 | 2019-12-04 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 殺虫剤としての二環式化合物 |
| JP6640126B2 (ja) | 2014-06-27 | 2020-02-05 | セルジーン コーポレイション | セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
| EP3925609B1 (en) | 2014-08-22 | 2025-07-30 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| TW201642857A (zh) | 2015-04-06 | 2016-12-16 | 西建公司 | 以組合療法治療肝細胞癌 |
| JP6727237B2 (ja) | 2015-07-02 | 2020-07-22 | セルジーン コーポレイション | 血液がん及び固形腫瘍の治療のための併用療法 |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| EA201890585A1 (ru) | 2015-08-27 | 2018-11-30 | Селджин Корпорейшн | Составы 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона |
| AU2016332236B2 (en) * | 2015-09-29 | 2019-04-11 | Kangpu Biopharmaceuticals, Ltd. | Pharmaceutical composition and application thereof |
| US10159675B2 (en) | 2015-12-02 | 2018-12-25 | Celgene Corporation | Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| DK3404024T3 (da) * | 2016-01-14 | 2021-01-11 | Kangpu Biopharmaceuticals Inc | Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| AU2017376704B2 (en) | 2016-12-16 | 2021-08-05 | Kangpu Biopharmaceuticals, Ltd. | Composition, application thereof and treatment method |
| US20200000776A1 (en) | 2017-02-13 | 2020-01-02 | Kangpu Biopharmaceuticals, Ltd. | Combination treating prostate cancer, pharmaceutical composition and treatment method |
| WO2018165142A1 (en) | 2017-03-07 | 2018-09-13 | Celgene Corporation | Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses |
| KR102014478B1 (ko) | 2017-05-12 | 2019-08-26 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN118638025A (zh) | 2017-08-21 | 2024-09-13 | 细胞基因公司 | 制备(s)-4,5-二氨基-5-氧代戊酸叔丁酯的工艺 |
| EP3679028A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Dihydroquinolinones |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| CN111278815B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 戊二酰亚胺 |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| WO2019142126A1 (en) | 2018-01-17 | 2019-07-25 | Aurigene Discovery Technologies Limited | Substituted alkynylene compounds as anticancer agents |
| WO2019164891A1 (en) | 2018-02-21 | 2019-08-29 | Celgene Corporation | Bcma-binding antibodies and uses thereof |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| US12263190B2 (en) | 2018-11-08 | 2025-04-01 | Juno Therapeutics, Inc. | Methods and combinations for treatment and T cell modulation |
| CN120698985A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| BR112021019669A2 (pt) | 2019-04-12 | 2021-12-07 | C4 Therapeutics Inc | Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno |
| WO2021105335A1 (en) | 2019-11-27 | 2021-06-03 | Captor Therapeutics S.A. | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
| AU2020392427B2 (en) | 2019-11-27 | 2024-03-07 | Captor Therapeutics S.A. | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
| WO2021168314A1 (en) * | 2020-02-21 | 2021-08-26 | Plexium, Inc. | Quinazolinone compounds and related compounds |
| IL299293A (en) | 2020-06-25 | 2023-02-01 | Celgene Corp | Cancer treatment methods with combined treatments |
| EP4185380A4 (en) * | 2020-07-24 | 2024-08-21 | Inipharm, Inc. | Quinazolinone hsd17b13 inhibitors and uses thereof |
| CA3186919A1 (en) | 2020-08-03 | 2022-02-10 | Sylvain Cottens | Low molecular weight protein degraders and their applications |
| US20230303539A1 (en) * | 2020-08-14 | 2023-09-28 | Shanghaitech University | Immunoregulatory compound and antitumor application thereof |
| CA3198024A1 (en) | 2020-11-13 | 2022-05-19 | Sampath Kumar Anandan | Dichlorophenol hsd17b13 inhibitors and uses thereof |
| WO2022146151A1 (en) | 2020-12-30 | 2022-07-07 | Captor Therapeutics S.A. | Novel compounds which bind to cereblon, and methods of use thereof |
| WO2022255890A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| WO2022255889A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| EP4480948A4 (en) * | 2022-02-14 | 2025-06-11 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | Compound based on a quinazoline-substituted glutarimide skeleton and use thereof |
| CN119325475A (zh) | 2022-06-06 | 2025-01-17 | C4医药公司 | 双环取代的戊二酰亚胺cereblon结合剂 |
| WO2024167423A1 (en) | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| CN116789530B (zh) * | 2023-05-16 | 2025-12-19 | 杭州师范大学 | 一种紫苏醇酚类衍生物及其制备方法和应用 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1997563A (en) * | 1929-05-31 | 1935-04-09 | Karmazin Engineering Company | Method of making heat radiators |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| DE69717831T3 (de) | 1996-07-24 | 2018-08-30 | Celgene Corp. | Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| KR100883184B1 (ko) * | 2000-12-11 | 2009-02-12 | 암젠 인코포레이션 | Ｃｘｃｒ3 길항제 |
| AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| AU2002343220A1 (en) | 2001-11-09 | 2003-05-19 | Matsushita Electric Industrial Co., Ltd. | Moving picture coding method and apparatus |
| FR2837201A1 (fr) * | 2002-03-18 | 2003-09-19 | Servier Lab | Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US20050024328A1 (en) | 2003-07-23 | 2005-02-03 | Graham Oldfield | Control area selection in a computing device with a graphical user interface |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| CA2545128C (en) | 2003-11-06 | 2010-01-12 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases |
| EP1687306A1 (en) | 2003-11-14 | 2006-08-09 | MERCK SHARP & DOHME LTD. | Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
| KR20120039065A (ko) | 2003-12-02 | 2012-04-24 | 셀진 코포레이션 | 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물 |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| BRPI0509019A (pt) | 2004-03-22 | 2007-08-07 | Celgene Corp | métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| MXPA06012278A (es) | 2004-04-23 | 2007-01-31 | Celgene Corp | Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de la hipertension pulmonar. |
| CN101098694A (zh) | 2004-11-12 | 2008-01-02 | 细胞基因公司 | 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物 |
| BRPI0518282A2 (pt) | 2004-11-23 | 2008-11-11 | Celgene Corp | uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio |
| GB0506147D0 (en) | 2005-03-24 | 2005-05-04 | Merck Sharp & Dohme | Therapeutic agents |
| CA2607929A1 (en) | 2005-05-11 | 2006-11-16 | Merck Sharp & Dohme Limited | 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1) |
| GB0509573D0 (en) | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
| US20090170849A1 (en) | 2006-04-05 | 2009-07-02 | Astrazeneca Ab | Quinazolinone derivatives having b-raf inhibitory activity |
| CN101415689A (zh) | 2006-04-05 | 2009-04-22 | 阿斯利康(瑞典)有限公司 | 具有抗癌活性的经取代的喹唑啉 |
| EP2010504A1 (en) | 2006-04-18 | 2009-01-07 | AstraZeneca AB | Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them |
| MX2009003038A (es) * | 2006-09-26 | 2009-04-15 | Celgene Corp | Derivados de quinazolinona 5-sustituidos como agentes antitumorales. |
| CA2704710C (en) | 2007-09-26 | 2016-02-02 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same |
| WO2011047129A1 (en) | 2009-10-15 | 2011-04-21 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
| WO2012027065A2 (en) | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| EP2640189A4 (en) | 2010-11-18 | 2014-03-19 | Deuteria Pharmaceuticals Inc | 3-deutero-pomalidomide |
| UA113512C2 (xx) | 2011-03-11 | 2017-02-10 | Тверда форма 3-(5-аміно-2-метил-4-оксо-4h-хіназолін-3-іл)піперидин-2,6-діону і її фармацевтична композиція та застосування | |
| JP6118273B2 (ja) | 2011-03-11 | 2017-04-19 | セルジーン コーポレイション | 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用 |
| EP2702410A2 (en) | 2011-04-29 | 2014-03-05 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| AU2013202104B2 (en) | 2012-01-13 | 2015-11-26 | Celgene Corporation | Biomarkers for the treatment of hepatocellular carcinoma |
| MX358517B (es) | 2012-06-29 | 2018-08-24 | Celgene Corp | Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon. |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| ES2814952T3 (es) | 2012-09-04 | 2021-03-29 | Celgene Corp | Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos |
| WO2014039960A1 (en) | 2012-09-10 | 2014-03-13 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
| CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| WO2014151180A1 (en) | 2013-03-14 | 2014-09-25 | Celgene Corporation | Treatment of psoriatic arthritis using apremilast |
| WO2014172429A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
| EP2986322A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| CA2909579A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
| US9067912B2 (en) | 2013-05-01 | 2015-06-30 | Celgene Corporation | Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,8-dione |
| WO2014179661A1 (en) | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
| MX386337B (es) | 2013-12-06 | 2025-03-18 | Celgene Corp | Métodos para determinar la eficacia del fármaco para el tratamiento de linfoma difuso de células b grandes, mieloma múltiple, y cánceres mieloides. |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US20150196562A1 (en) | 2014-01-15 | 2015-07-16 | Celgene Corporation | Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| WO2015107196A1 (en) | 2014-01-20 | 2015-07-23 | Institut Curie | Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation |
| EP3116872A4 (en) | 2014-03-14 | 2017-08-30 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| MX387318B (es) | 2014-04-14 | 2025-03-18 | Arvinas Operations Inc | Moduladores de la proteólisis basados en imida y métodos de uso asociados. |
| JP6640126B2 (ja) | 2014-06-27 | 2020-02-05 | セルジーン コーポレイション | セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
| CA2954652A1 (en) | 2014-07-11 | 2016-01-14 | Celgene Corporation | Combination therapy for cancer |
| WO2016014890A1 (en) | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
| US10316030B2 (en) | 2014-08-07 | 2019-06-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
| EP3188745A1 (en) | 2014-08-15 | 2017-07-12 | Celgene Corporation | Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition |
| US20170242014A1 (en) | 2014-10-13 | 2017-08-24 | Celgene Corporaton | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
| WO2016153948A1 (en) | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders |
| EP3277676B1 (en) | 2015-03-25 | 2023-03-22 | Pierre Fabre Médicament | Substituted quinazoline derivatives as dna methyltransferase inhibitors |
| TW201642857A (zh) | 2015-04-06 | 2016-12-16 | 西建公司 | 以組合療法治療肝細胞癌 |
-
2007
- 2007-09-25 MX MX2009003038A patent/MX2009003038A/es active IP Right Grant
- 2007-09-25 LT LTEP11174059.3T patent/LT2428513T/lt unknown
- 2007-09-25 PL PL11174055T patent/PL2420497T3/pl unknown
- 2007-09-25 CL CL200702752A patent/CL2007002752A1/es unknown
- 2007-09-25 PL PL11174059T patent/PL2428513T3/pl unknown
- 2007-09-25 EP EP11174059.3A patent/EP2428513B1/en active Active
- 2007-09-25 UA UAA200904043A patent/UA94964C2/ru unknown
- 2007-09-25 JP JP2009530406A patent/JP5388854B2/ja not_active Expired - Fee Related
- 2007-09-25 RS RS20160160A patent/RS54607B1/sr unknown
- 2007-09-25 SI SI200731953T patent/SI2428513T1/sl unknown
- 2007-09-25 KR KR1020097008299A patent/KR101414786B1/ko not_active Expired - Fee Related
- 2007-09-25 PT PT111740569T patent/PT2420498T/pt unknown
- 2007-09-25 HR HRP20120447TT patent/HRP20120447T1/hr unknown
- 2007-09-25 RS RS20120259A patent/RS52349B/sr unknown
- 2007-09-25 EP EP07838876A patent/EP2066656B1/en active Active
- 2007-09-25 CN CN201710560709.0A patent/CN107445940A/zh active Pending
- 2007-09-25 PL PL11174056T patent/PL2420498T3/pl unknown
- 2007-09-25 PT PT07838876T patent/PT2066656E/pt unknown
- 2007-09-25 CN CN201510162174.2A patent/CN105017212A/zh active Pending
- 2007-09-25 ME MEP-2016-47A patent/ME02420B/me unknown
- 2007-09-25 NZ NZ575830A patent/NZ575830A/en unknown
- 2007-09-25 LT LTEP11174056.9T patent/LT2420498T/lt unknown
- 2007-09-25 AT AT07838876T patent/ATE555104T1/de active
- 2007-09-25 ES ES11174056.9T patent/ES2633818T3/es active Active
- 2007-09-25 EP EP11174056.9A patent/EP2420498B1/en active Active
- 2007-09-25 SI SI200731756T patent/SI2420497T1/sl unknown
- 2007-09-25 CA CA2663731A patent/CA2663731C/en not_active Expired - Fee Related
- 2007-09-25 DK DK11174059.3T patent/DK2428513T3/en active
- 2007-09-25 ES ES07838876T patent/ES2385680T3/es active Active
- 2007-09-25 WO PCT/US2007/020765 patent/WO2008039489A2/en not_active Ceased
- 2007-09-25 CN CN2012103629552A patent/CN102898416A/zh active Pending
- 2007-09-25 MY MYPI20091187 patent/MY150699A/en unknown
- 2007-09-25 HU HUE11174056A patent/HUE035308T2/en unknown
- 2007-09-25 ES ES11174059.3T patent/ES2634915T3/es active Active
- 2007-09-25 ME MEP-2017-152A patent/ME02890B/me unknown
- 2007-09-25 DK DK07838876.6T patent/DK2066656T3/da active
- 2007-09-25 ME MEP-2017-159A patent/ME02829B/me unknown
- 2007-09-25 HU HUE11174055A patent/HUE026827T2/en unknown
- 2007-09-25 ME MEP-2012-60A patent/ME01421B/me unknown
- 2007-09-25 ZA ZA200901950A patent/ZA200901950B/xx unknown
- 2007-09-25 SI SI200730915T patent/SI2066656T1/sl unknown
- 2007-09-25 CN CNA2007800426159A patent/CN101535291A/zh active Pending
- 2007-09-25 RU RU2009115653/04A patent/RU2463298C2/ru active
- 2007-09-25 SI SI200731950T patent/SI2420498T1/sl unknown
- 2007-09-25 CN CN201510163088.3A patent/CN104910133A/zh active Pending
- 2007-09-25 HU HUE11174059A patent/HUE035389T2/en unknown
- 2007-09-25 EP EP11174055.1A patent/EP2420497B1/en active Active
- 2007-09-25 DK DK11174055.1T patent/DK2420497T3/en active
- 2007-09-25 ES ES11174055.1T patent/ES2564935T3/es active Active
- 2007-09-25 PL PL07838876T patent/PL2066656T3/pl unknown
- 2007-09-25 CN CN201510163104.9A patent/CN104876908A/zh active Pending
- 2007-09-25 DK DK11174056.9T patent/DK2420498T3/en active
- 2007-09-25 RS RS20170707A patent/RS56279B1/sr unknown
- 2007-09-25 PT PT111740593T patent/PT2428513T/pt unknown
- 2007-09-25 EP EP17165492.4A patent/EP3239144A1/en not_active Withdrawn
- 2007-09-26 TW TW096135832A patent/TWI399372B/zh not_active IP Right Cessation
- 2007-09-26 TW TW102116418A patent/TWI522351B/zh not_active IP Right Cessation
- 2007-09-26 US US11/904,551 patent/US7635700B2/en active Active
- 2007-09-26 AR ARP070104264A patent/AR063015A1/es active IP Right Grant
- 2007-09-26 PE PE2007001298A patent/PE20080970A1/es active IP Right Grant
-
2009
- 2009-03-19 IL IL197716A patent/IL197716A/en active IP Right Grant
- 2009-03-25 NI NI200900040A patent/NI200900040A/es unknown
- 2009-04-14 CR CR10712A patent/CR10712A/es unknown
- 2009-04-23 CO CO09041135A patent/CO6160323A2/es unknown
- 2009-12-11 US US12/636,651 patent/US8921385B2/en active Active
-
2012
- 2012-06-13 CY CY20121100536T patent/CY1112860T1/el unknown
- 2012-06-29 RU RU2012127334A patent/RU2617989C2/ru active
-
2013
- 2013-08-18 IL IL228017A patent/IL228017A/en active IP Right Grant
- 2013-10-08 JP JP2013210802A patent/JP5901599B2/ja not_active Expired - Fee Related
-
2014
- 2014-11-24 US US14/552,337 patent/US9732064B2/en active Active
-
2015
- 2015-11-06 JP JP2015218025A patent/JP6133383B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-14 HR HRP20160266TT patent/HRP20160266T1/hr unknown
- 2016-07-12 AR ARP160102114A patent/AR105340A2/es unknown
-
2017
- 2017-02-28 IL IL250847A patent/IL250847A0/en unknown
- 2017-04-18 RU RU2017113360A patent/RU2017113360A/ru not_active Application Discontinuation
- 2017-04-19 JP JP2017082496A patent/JP2017165744A/ja not_active Ceased
- 2017-07-07 US US15/644,119 patent/US20170369471A1/en not_active Abandoned
- 2017-07-17 HR HRP20171093TT patent/HRP20171093T1/hr unknown
- 2017-07-18 HR HRP20171106TT patent/HRP20171106T1/hr unknown
- 2017-07-20 CY CY20171100778T patent/CY1119248T1/el unknown
- 2017-08-02 CY CY20171100831T patent/CY1119176T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016053066A5 (enExample) | ||
| HRP20171106T1 (hr) | 5-supstituirani kinazolinonski derivati kao sredstva protiv raka | |
| JP6448726B2 (ja) | ４’−ｏ−置換イソインドリン誘導体および該誘導体を含有する組成物およびその使用方法 | |
| AU2018360847B2 (en) | Modulators of the integrated stress pathway | |
| EP3256463B1 (en) | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists | |
| CN109789146B (zh) | 趋化因子受体调节剂及其用途 | |
| JP6466171B2 (ja) | 新規アミン誘導体またはその塩 | |
| CN103702992B (zh) | 通过吡唑酸与邻氨基苯甲酸酯反应制备四唑取代的邻氨基苯甲酸二酰胺衍生物的方法 | |
| AU641052B2 (en) | 3-amidoindolyl derivatives | |
| JP2005530722A5 (enExample) | ||
| JP2014508811A5 (enExample) | ||
| JP2020521767A5 (enExample) | ||
| WO2005040112A1 (en) | Compounds with pgd2 antagonist activity | |
| CN103764649B (zh) | 通过苯并噁嗪酮与胺反应制备四唑取代的邻氨基苯甲酸二酰胺衍生物的方法 | |
| JP2013535220A5 (enExample) | ||
| JP2014526510A5 (enExample) | ||
| JP2013047244A5 (enExample) | ||
| AU2002360621A1 (en) | Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 | |
| CN101031545A (zh) | 异吲哚啉化合物和其使用方法 | |
| JP2018135343A5 (enExample) | ||
| JP2017508733A5 (enExample) | ||
| JP2018522925A5 (enExample) | ||
| JP2017507175A5 (enExample) | ||
| JP2012528839A5 (enExample) | ||
| JP2017532377A5 (enExample) |